Ankyra Therapeutics reported the appointment of Robert V. Tighe, as chief scientific officer. Tighe joined the team on July 10, and brings considerable immuno-oncology drug development experience to the company. Tighe began his career as a research assistant in the laboratory of Dr. Robert Weinberg at the Massachusetts Institute of Technology (MIT).

He has over 20 years of industry experience and has previously served as associate director of immunopharmacology at EMD Serono, vice-president of translational immunology and immunopharmacology at Compass Therapeutics, and most recently was vice-president of research at TCR2 Therapeutics.